 |
 |
Here's another tidbit I noticed in the Spring '98 NPF Parkinson Report .... The first phase of human testing of recombinant GDNF has started to determine determine safety, tolerability and potential benefit in patients with PD. Patients eligible for the study include those with moderate to advanced symptoms. They must be medically able to undergo surgery, because the material is administered into the brain by an investigational device. Participating centers are in the following cities: Charlottesville, VA Chicago, IL Houston, TX Portland, OR Toronto, Ontario Miami, Fl Phoenix, AZ Minneapolis, MN Englewood, CO Email me privately for contact names and numbers at these centers, or call NPF at 1-800-327-4545; in Florida 1-800-433-7022; in California 1-800-400-8448. Mary Rack cg for late mother, Louise